Invivoscribe Marketing, Author at Invivoscribe

About Invivoscribe Marketing

This author has not yet filled in any details.
So far Invivoscribe Marketing has created 123 blog entries.

Critical Mistakes to Avoid when Developing a Drug/CDx Combination for International Registrations

Invivoscribe Marketing2022-05-25T03:00:58-07:00August 24th, 2021|2021 Videos, Featured Videos, Videos|

Watch video

Invivoscribe Announces Key Submission in the EU, Expanded Presence and Activity in China

Invivoscribe Marketing2021-07-22T17:27:56-07:00July 22nd, 2021|2021 Press Releases, Press Releases|

A Streamlined Laboratory Workflow for Controlling Antibody and Reagent Lots on a 12C Flow Cytometry System

Invivoscribe Marketing2022-05-25T03:00:58-07:00July 15th, 2021|2021 Videos, 2021 Webinars, Featured Videos, Videos, Webinars|

Watch video

Immunoglobulin gene rearrangement in Koreans with multiple myeloma: Clonality assessment and repertoire analysis using next-generation sequencing

Invivoscribe Marketing2022-09-07T22:31:04-07:00June 24th, 2021|2021 Publications, Featured Publications, Publications|

Assessment of MRD by NGS in Daily Clinical Management of Multiple Myeloma

Invivoscribe Marketing2022-05-25T03:00:58-07:00June 14th, 2021|2021 Videos, Featured Videos, Videos|

Watch video

New Frontiers in Hematology: From CLL Tumor Precursor Cells to Tracking Disease Burden in Multiple Myeloma

Invivoscribe Marketing2022-05-25T03:00:58-07:00June 14th, 2021|2021 Videos, Featured Videos, Videos|

Watch video

Validation of a Next-Generation Sequencing-based T-Cell Receptor Gamma Gene Rearrangement Diagnostic Assay: Transitioning from Capillary Electrophoresis to Next-Generation Sequencing

Invivoscribe Marketing2021-04-27T17:17:21-07:00April 20th, 2021|2021 Publications, Publications|

AMP

Validation of an NGS based assay for monitoring FLT3 ITD and TKD variants in AML subjects

Invivoscribe Marketing2021-03-05T20:49:11-08:00March 5th, 2021|2019 Posters, AMP, Posters|

AMP

Evaluation of An Alternative Fragmentation Method in High Throughput NGS Sample Testing of Minimal Residual Disease in Hematological Malignancies

Invivoscribe Marketing2021-03-05T20:44:34-08:00March 5th, 2021|2019 Posters, AMP, Posters|

AMP

Comparing DNA Extraction Methods for the LymphoTrack^® IVD TRG Assay

Invivoscribe Marketing2021-03-05T20:38:02-08:00March 5th, 2021|2019 Posters, AMP, Posters|

AMP

A Next-Generation Sequencing Based Analysis of Clonality across 39 Subjects Treated for Lymphoproliferative Disorders Reveals Matching Clones in the Diverse IGH Locus

Invivoscribe Marketing2021-03-03T23:53:52-08:00March 3rd, 2021|2019 Posters, AMP, Posters|

EHA

TRG Clonality Interrogation by CE and NGS: Bridging the Gap Between Classical and Leading Edge Technologies

Invivoscribe Marketing2021-03-03T23:55:00-08:00March 3rd, 2021|2020 Posters, EHA, Posters|

ASH

End of Treatment Peripheral Blood TCR Evaluation for Minimal Residual Disease Evaluation in Peripheral T-cell Lymphomas

Invivoscribe Marketing2021-03-03T23:40:33-08:00March 3rd, 2021|2020 Posters, ASH, Posters|

Complementary Value of MRD Assessments by NGS and MFC for the Study of Hematologic Malignancies

Invivoscribe Marketing2022-05-25T03:00:58-07:00December 1st, 2020|2020 Videos, 2020 Webinars, Videos, Webinars|

Watch video

Validation and interpretation of IGH and TCR clonality testing by Ion Torrent S5 NGS for diagnosis and disease monitoring in B and T cell cancers

Invivoscribe Marketing2021-02-11T19:51:54-08:00November 25th, 2020|2020 Publications, Publications|

Classification of intestinal T‐cell receptor repertoires using machine learning methods can identify patients with coeliac disease regardless of dietary gluten status

Invivoscribe Marketing2021-02-11T19:57:34-08:00November 22nd, 2020|2020 Publications, Publications|

Routine Evaluation of Minimal Residual Disease in Myeloma Using Next-Generation Sequencing Clonality Testing

Invivoscribe Marketing2021-02-17T18:10:07-08:00November 17th, 2020|2020 Publications, Featured Publications, Publications|

Artificial Intelligence (AI) and other Data Science Applications in Molecular Pathology

Invivoscribe Marketing2022-05-25T03:00:58-07:00November 16th, 2020|2020 Videos, Videos|

Watch video

Clinical Utility of NGS in Lymphoid Malignancies including Minimal Residual Disease (MRD) testing

Invivoscribe Marketing2022-05-25T03:00:58-07:00November 16th, 2020|2020 Videos, Videos|

Watch video

Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma

Invivoscribe Marketing2021-02-11T20:05:42-08:00October 30th, 2020|2020 Publications, Publications|

Plasticity of the human IgM repertoire in response to long‐term spaceflight

Invivoscribe Marketing2021-02-11T20:09:45-08:00October 13th, 2020|2020 Publications, Featured Publications, Publications|

Immune recovery in patients with mantle cell lymphoma receiving long-term ibrutinib and venetoclax combination therapy

Invivoscribe Marketing2021-02-11T20:11:02-08:00October 8th, 2020|2020 Publications, Publications|

Genetic evolution of in situ follicular neoplasia to aggressive B-cell lymphoma of germinal center subtype

Invivoscribe Marketing2021-02-11T20:13:51-08:00August 27th, 2020|2020 Publications, Publications|

Baseline VDJ clonotype detection using a targeted sequencing NGS assay: allowing for subsequent MRD assessment

Invivoscribe Marketing2021-02-11T20:26:38-08:00July 22nd, 2020|2020 Publications, Publications|

VIRTUAL EHA: Next Generation Analysis in CLL and Other Malignancies

Invivoscribe Marketing2022-05-25T03:00:59-07:00June 14th, 2020|2020 Videos, Featured Videos, Videos|

Watch video

The Laboratory for Personalized Molecular Medicine® (LabPMM®) at Invivoscribe offer internationally standardized testing of novel and proprietary biomarkers that are critically important for patient care.

Lymphoma

Myeloma

Browse our comprehensive menu of product & testing services.

A proven strategy to accelerate drug approvals

Design Controls, Bioinformatics Software, Identify & Track, Custom Development, and Complementary MRD Assays

cGMP Compliant, CE-marked IVDs & CDx Manufacturing, Assay Development, and Controls & Reagents

Clinical Lab Experience, Internationally Standardized, Comprehensive Panels, Complementary MRD Assays, and Worldwide Enrollment

Accredited & Proven, Registered Medical Device Establishment, Multiple CDx Approvals, CE-marked IVDs, and Marketing Authorization Holder (MAH)

We take pride in expanding the science that bridges personalized medicine with quality healthcare.

Personalized Molecular Medicine® is use of genomics and patient specific information to identify optimal treatment for each patient.

November 17th, 2020 Routine Evaluation of Minimal Residual Disease in Myeloma Using Next-Generation Sequencing Clonality Testing

April 20th, 2021 Validation of a Next-Generation Sequencing-based T-Cell Receptor Gamma Gene Rearrangement Diagnostic Assay: Transitioning from Capillary Electrophoresis to Next-Generation Sequencing

November 17th, 2020 Routine Evaluation of Minimal Residual Disease in Myeloma Using Next-Generation Sequencing Clonality Testing

Lymphoma

Myeloma

Browse our comprehensive menu of product & testing services.

About Invivoscribe Marketing

Title

The Laboratory for Personalized Molecular Medicine^® (LabPMM^®) at Invivoscribe offer internationally standardized testing of novel and proprietary biomarkers that are critically important for patient care.

Personalized Molecular Medicine^® is use of genomics and patient specific information to identify optimal treatment for each patient.

November 17th, 2020
Routine Evaluation of Minimal Residual Disease in Myeloma Using Next-Generation Sequencing Clonality Testing

April 20th, 2021
Validation of a Next-Generation Sequencing-based T-Cell Receptor Gamma Gene Rearrangement Diagnostic Assay: Transitioning from Capillary Electrophoresis to Next-Generation Sequencing

November 17th, 2020
Routine Evaluation of Minimal Residual Disease in Myeloma Using Next-Generation Sequencing Clonality Testing